 |
|
|
| |
Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-Experienced Patients Enrolled Into the MOTIVATE Studies and Who Received Maraviroc + Optimized Background Therapy
|
| |
| |
Reported by Jules Levin
CROI 2010 SF, Feb 16-19
Marilyn Lewis1, Paul Simpson1, Christophe Delogne1, John Sullivan1, Hernan Valdez3, Richard Harrigan2 and Mike Westby1
1Pfizer Global R&D, Sandwich, Kent, UK; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3Pfizer Inc. New York, NY
|
| |
|
|
|
|
|
